CLDIEarnings•globenewswire•
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Sentiment:Negative (20)
Summary
SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 8, 2025 by globenewswire